Jesse's Journey Foundation

Defeat Duchenne. Change Lives.

News & Resources

Welcome to 2018!

It’s 2018 – happy new year! When the calendar changes over, it always seems to bring about feelings of a fresh start, another chance to achieve any of the goals that haven’t been checked off the “to do” list yet. For Jesse’s Journey, 2018 isn’t just another year. We’re celebrating the 20th anniversary of John […]


Summit Therapeutics plc : Interim 24-Week Data from PhaseOut DMD

Summit Therapeutics plc(‘Summit’, or ‘the Company’) EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMIT’S PhaseOut DMD CLINICAL TRIAL Increase in Utrophin Protein Expression Observed Summit Accelerating Preparations for Pivotal Clinical Trial Ezutromid is a Potential Disease-Modifying Treatment for the Entire DMD Patient Population Conference Call Scheduled for 1:00pm GMT […]


First Duchenne Muscular Dystrophy Patient Dosed in Systemic Microdystrophin Gene Therapy

HACKENSACK, N.J., Jan. 17, 2018 /PRNewswire-USNewswire/ — Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced that the first Duchenne patient has been dosed with microdystrophin gene therapy by Dr. Jerry Mendell, Dr. Louise Rodino-Klapac, and their team at Nationwide Children’s Hospital. This trial was funded in part by a $2.2 million grant from […]


FDA Grants Orphan Drug Designation to OPMD Therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to an oculopharyngeal muscular dystrophy (OPMD) therapy. Benitec Biopharma’s BB-301 therapy, a single vector (gene therapy construct) system, was granted the designation almost exactly a year after receiving the same designation from a European Medicines Agency (EMA) committee. The therapy silences the expression […]


Pharma Giants Form UK-Based ‘Project Hercules’ to Generate Evidence for DMD Treatments

Seven pharmaceutical companies are banding together to sponsor Project Hercules — an initiative that addresses evidence generation for Duchenne muscular dystrophy (DMD) treatments. The project, led by the non-profit organization Duchenne UK, aims to simplify the way evidence is generated for health technology assessments by authorities such as Great Britain’s National Institute for Health and Care Excellence […]


Recent developments in Duchenne muscular dystrophy: facts and numbers

Muscular dystrophies are a clinically and genetically heterogeneous group of skeletal muscle‐wasting diseases. Even for experts in the field of neuromuscular diseases, it is becoming increasingly difficult to distinguish and accurately diagnose all forms of muscular dystrophy on clinical grounds alone, as there is currently a still growing number of different genetic loci for muscular […]


Scientists Develop Skeletal Muscle Using Stem Cells

Researchers have taken a major step towards developing a stem cell replacement therapy for debilitating muscle diseases. A team from UCLA have developed a new strategy to efficiently isolate, mature and transplant skeletal muscle cells created from human pluripotent stem cells, which can produce all cell types of the body. The findings could pave the […]


Investigational Therapy SR8278 Shown to Regenerate Muscle in DMD Mice Study

Scientists at Saint Louis University believe that an investigational therapy called SR8278 holds potential for treating Duchenne muscular dystrophy (DMD) after it was shown to increase muscle function and decrease muscle fibrosis in lab mice. The discovery follows the team’s research of the nuclear receptor REV-ERB, which regulates key processes in the body, including muscle generation, […]


Update from PTC Therapeutics

Dear Duchenne Community, As we enter the holiday season, I wanted to thank the community for all your support throughout the regulatory process for Translarna™ (ataluren) with the FDA. Your voice as passionate advocates has been instrumental in this process. As you know, we filed a Formal Dispute Resolution Request (FDRR) with the FDA a […]


Disclaimer: Jesse's Journey provides the above information as a potential resource for our visitors. We do not verify the accuracy or truth of third party information and cannot be responsible for the quality of the information or services provided by other organizations and mentioned on our website, nor do we endorse any service, product, treatment or therapy.